Atomo Diagnostics Ltd. · ASX:AT1
Atomo Diagnostics — FY2022 Earnings Presentation
31 slides from Atomo Diagnostics's earnings presentation, Aug 25, 2022
Slide 1: FY22 Results
Atomo Dia gnos tics Limite d Au t h o ris e d b y J o h n Ke lly, Ma n a g in g Dire c t o r Le ve l 1, 3 -5 Ge o rg e St re e t Le ic h h a rd t NSW 20 4 0 Au s t ra lia FY22 RES ULTS 2 5 AUGUST 2 0 2 2 ATOMO DIAGNOS TICS LIMITED | (AS X: AT1) PRIVATE AND CONFIDENTIAL ATOMO DIAGNOSTICS LIMITED | (A
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on omissions from, any other written or oral communications transmitted or otherwise made information available as at the date of this presentation. The information in this available to the recipient in conne
Slide 3: Key Value Drivers
KEY VALUE DRIVERS 1 A visionary diagnostics company reimaging consumer focused testing and delivering best in class usability in the growing point of care and decentralised test market Strong financial position, committed investors, an experienced board & 2 management team and a motivated cohort of
Slide 4: Company Summary
CO MPANY SUMMARY Atomo Diagnostics Limited (ASX: AT1) is an innovative medical device diagnostics company supplying unique, integrated user friendly rapid diagnostic test (RDT) devices and finished point-of-care rapid tests to global partners Headquartered in Australia and listed on the ASX, Atomo d
Slide 5: FY22 Key Achievements and Challenges
F Y2 2 KEY ACHIEVEMENTS AND CHALLENGES Completion of industralisation of operations to support volume production of 1 Atomo products, including blister manufacturing – up to 18 million per annum of installed cassette capacity now available Successful participation in the local COVID-19* market with
Slide 6: FY22 Financial Results
FY22 FINANCIAL RESULTS ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) PRIVATE AND CONFIDENTIAL 6
Slide 7: FY22 - Profit & Loss
F Y2 2 - P RO F IT & LO SS AUD FY22($m) FY21($m) (%) Annual Sales Revenue ($m) Revenue 12.34 6.72 84% Cost of sales (8.09) (3.30) (145%) Gross Profit 4.25 3.42 24% 14.0 Gross Margin 34% 51% 12.0 10.0 Licence and settlement fee income 1.65 - 100% 8.0 Total revenue 13.99 6.72 108% 6.0 Gross Margin (in
Slide 8: FY22 - Balance Sheet
F Y2 2 - BALANCE SHEET FY22 FY21 • Cash balance of $12.97m at 30 June 22 and debt free AUD ($m) ($m) • COVID-19 stock on hand at year end continuing to be sold Cash and cash equivalents 12.97 17.95 over FY23 Trade and other receivables 2.68 4.49 • Continued investment in manufacturing and production
Slide 9: FY22 - Cash Flow
F Y2 2 - CASH F LOW • Cash receipts of $16.39m from customers as strong COVID sales, together with growing HIV business and the settlement and licence fees from Access Bio, drove cash inflows • Cash payments for stock of $8.83m related primarily to purchase of COVID-19 rapid tests, a number of which
Slide 10: Business Summary
BUSINESS SUMMARY ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) PRIVATE AND CONFIDENTIAL 10
Slide 11: Atomo's Strategic Focus
ATO MO ’S STRATEGIC FO CUS CO RE CAP ABILITIES Innovation, Co-development & Commercialisation (Device Design, Usability, Manufacturability, IP, Regulatory, Co-commercialisation) MARKETS Consumer Health Infectious Diseases Testing OEM Devices (HIV, COVID, HCV and Others) & Wellness (Devices, Componen
Slide 12: Product Channels
P RO DUCT CHANNELS CHANNELS* Consumer Health Infectious Diseases Testing OEM Devices (HIV, COVID, HCV and Others) & Wellness (Blisters, Devices, Components, Licenses) (Retail and Emerging Telehealth) Healthcare Distributors Diagnostics companies suppling finished rapid tests Direct to consumer healt
Slide 13: Unique Technology & Know How
UNIQ UE TECHNO LO GY & KNOW HOW ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) PRIVATE AND CONFIDENTIAL 13
Slide 14: Atomo's Blood Testing Solutions
ATO MO ’S BLO O D TESTING SO LUTIO NS * ** IN MARKET Galileo: supports professional & self- test applications. WHO Prequalified. Pascal: with integrated buffer, supports professional & self-test applications: Pregnancy test, NG – CE Mark FebriDx, Lumos – CE Mark and TGA Elion: Specially designed to
Slide 15: Atomo Swab Platform
ATO MO SWAB P LATFO RM The Atomo Swab Platform is a unique (patent pending*) device developed using Atomo’s existing core IP and knowhow. Developed to improve usability and performance of swab-based rapid tests, this product expands Atomo’s product range beyond blood-based testing. Designed to suppo
Slide 16: Operational Capability & Expertise
O P ERATIO NAL CAPABILITY & EXP ERTISE Atomo’s Gen II Blister machine currently being qualified in Sydney Atomo has used proceeds from the IPO to expand its manufacturing capabilities to enable the company to commercialise a larger range of finished home tests, and to deliver improved economics for
Slide 17: Regulatory Approvals
REGULATO RY AP P ROVALS CE MARK ( Notified Body BSI ) : PASCAL and GALILEO – both approved for Professional Use and Self Test SymplitudebyMe HIV Self Test (Atomo), AtomoRapid HIV Prof. Use (Atomo), Pregnancy hCG Prof use (NG Bio), Pregnancy hCG Self-Test (NG Bio), FebriDx AMR screen Prof. Use (Lumos
Slide 18: A Leading HIV Rapid Test
A LEADING HIV RAP ID TEST Atomo has developed and successfully launched the world’s first integrated, blood-based RDT solutions for professional use and self-test HIV screening: • With regulatory approvals including CE Mark for Europe, Australian TGA, and prequalification by the World Health The Ato
Slide 19: Other Finished Tests
OTHER F INISHED TESTS Atomo has partnered with NG Biotech and Lumos Diagnostics to provide the cassettes used to produce the Blood Precision hCG Pregnancy Test and FebriDx Antimicrobial Resistance (AMR) screening tests • The Blood Precision hCG pregnancy test offers results in 5 minutes and is sold
Slide 20: Growth Strategy
GROW TH STRATEGY ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) PRIVATE AND CONFIDENTIAL 20
Slide 21: Diagnostic Landscape and Trends
DIAGNO STIC LANDSCAP E AND TRENDS HIV P O INT O F CARE P RO LIF ERATIO N COVID 19 has transformed the diagnostic Growth in rapid testing testing landscape • Growing demand for reliable, rapid and decentralised diagnostic testing for patients at POC and in their homes * • While Central Lab testing cu
Slide 22: Expanding Demand for OEM Supply
Marke EXPANDING DEMAND FO R O EM SUP P LY HIV t P o st COVID, At o m o is a c t ive ly e n g a g in g w it h a re c e p t ive d ia g n o st ic m a rke t Resurgent Interest in New Products and Home Testing • Atomo has seen an increase in enquiries and interest in new test development alongside a sign
Slide 23: Finished Product Strategy
F INISHED P RO DUCT STRATEGY Over the last 6 months, Atomo has been focusing on development of P RO DUCT REQ UIREMENTS a go-to-market and product partnership strategy involving a number of key elements shown REGULATORY PATH • Channel partner feedback on prioritisation of customer REQUIREMENTS demand
Slide 24: Commercialisation Product Roadmap
CO MMERCIALISATIO N P RO DUCT ROADMAP Atomo has reviewed the changing point of care test landscape post pandemic, including engagement with emerging eHealth companies now opening up home based healthcare. This assessment of emerging product demand, technical feasibility, regulatory pathway and go-to
Slide 25: Strategy for FY23 and Beyond
STRATEGY FO R F Y2 3 AND BEYO ND Switching focus and investment from expansion of installed manufacturing capacity (now complete) to commercial scale up and business development, including focusing on: • Expansion of senior commercial resourcing and associated engagement with market and channel part
Slide 26: Appendix
Atomo Dia gnos tics Limite d Le ve l 1, 3 -5 Ge o rg e St re e t Le ic h h a rd t NSW 20 4 0 Au s t ra lia AP P ENDIX 2 3 AUGUST 2 0 2 2 ATOMO DIAGNOS TICS LIMITED | (AS X: AT1) PRIVATE AND CONFIDENTIAL ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) PRIVATE AND CONFIDENTIAL
Slide 27: Our Team - Board
O UR TEAM Bo a rd J o h n Ke it h Dr. Cu rt La Be lle De b o ra h J . Ne ff Dr. P a u l Ka s ia n Non -Executive Chair Non -Executive Director Non -Executive Director Non -Executive Director Mr. Keith is one of the Managing Dr. LaBelle has been actively A veteran of the life sciences industry Dr. Ka
Slide 28: Our Team - Executive Team
O UR TEAM Exe c u t ive Te a m J o h n Ke lly W ill So u t e r Ch a n d ra Su ku m a r Dr. Ma rilyn Cla rke Founder, Managing Director Chief Financial Officer Chief Operating Officer Director, Quality Assurance and CEO & Regulatory Affairs Before founding Atomo Diagnostics Experienced senior finance
Slide 29: Our Team - Commercial Team
O UR TEAM Co m m e rc ia l Te a m J im Mc Me n a m y An n a Tu c ke r J a s o n Ka va n a g h Head of Business Development Vice President of Business Business Development and Partnerships – U.S.A Development - Europe Manager - APAC Mr. McMenamy has over 30 years of Ms. Tucker brings to Atomo a prove
Slide 30: Company History
CO MPANY HISTO RY Recent Milestones • 2010: Atomo formed to address Australian TGA Atomo Deal with Galileo secures Atomo A$16m in HIV Self Test unmet user needs and reliability approves Atomo successfully Accessbio for FDA EUA with incorporates customer secures WHO issues in point of care testing HI
Slide 31: Patented Portfolio
PATENTED P O RTFO LIO * • Family 1: Diagnostic System PCT/AU2011/000315 Relates to an integrated test system incorporating lancet, test, and internal buffer reservoir. The system is such that buffer is brought into contact with the test component only after the sample has been delivered to the test.